Adlai Nortye Group Ltd (ANL) Stock AnalysisANLAdlai Nortye Group Ltd

Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.

Adlai Nortye Ltd (ANL) appears to be a good buy right now. The current price is $15.62, which is significantly lower than the average analyst price target of $31, indicating a potential upside of 98.5%. Additionally, the stock has shown a remarkable year-to-date change of +1031.88%, reflecting strong momentum. However, the main risk is the forward P/E ratio of -43.24, suggesting potential challenges in profitability that investors should monitor closely.